Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALRNNASDAQ:CLRBNASDAQ:ONCSNASDAQ:SAVANASDAQ:SNNA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$5.06+2.6%$5.41$1.01▼$7.42$85.87M2.22137,819 shs80,550 shsCLRBCellectar Biosciences$3.02-1.3%$3.63$1.33▼$4.45$97.43M0.92945,448 shs678,612 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shsSAVACassava Sciences$22.19+2.1%$21.44$12.32▼$32.10$959.72M-0.45756,810 shs5,439 shsSNNASienna Biopharmaceuticals$0.14$0.14$0.06▼$3.80$4.20M2.671.87 million shs13.32 million shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics+2.64%+1.20%-12.46%+0.40%+255.09%CLRBCellectar Biosciences-1.31%-0.66%-21.56%-19.47%+106.71%ONCSOncoSec Medical0.00%0.00%0.00%0.00%-68.50%SAVACassava Sciences+4.77%+2.55%+10.25%-10.32%+40.91%SNNASienna Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%The Gold Grab of the Century (Ad)When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron Therapeutics1.5938 of 5 stars3.53.00.00.01.41.70.0CLRBCellectar Biosciences2.2153 of 5 stars3.54.00.00.02.50.00.6ONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/ASAVACassava Sciences3.255 of 5 stars3.50.00.04.72.30.00.6SNNASienna BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics3.00Buy$19.00275.49% UpsideCLRBCellectar Biosciences3.00Buy$20.00562.25% UpsideONCSOncoSec MedicalN/AN/AN/AN/ASAVACassava Sciences3.00Buy$124.00458.81% UpsideSNNASienna BiopharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest ALRN, CLRB, ONCS, SAVA, and SNNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024ALRNAileron TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $19.003/28/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $28.003/28/2024CLRBCellectar BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $12.003/5/2024SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$124.003/4/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ACLRBCellectar BiosciencesN/AN/AN/AN/A($0.36) per shareN/AONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/ASAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/ASNNASienna BiopharmaceuticalsN/AN/AN/AN/A$1.27 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$15.73M-$3.38N/AN/AN/AN/A-130.32%-39.23%5/13/2024 (Estimated)CLRBCellectar Biosciences-$37.98M-$3.10N/AN/AN/AN/A-3,821.29%-280.23%5/2/2024 (Estimated)ONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/ASAVACassava Sciences-$97.22M-$2.32N/A13.29N/AN/A-57.53%-52.58%5/6/2024 (Estimated)SNNASienna Biopharmaceuticals-$73.47M-$3.59N/AN/AN/AN/A-177.36%-52.22%N/ALatest ALRN, CLRB, ONCS, SAVA, and SNNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/15/2024Q4 2023ALRNAileron TherapeuticsN/A-$1.54-$1.54-$1.54N/AN/A3/27/2024Q4 2023CLRBCellectar Biosciences-$0.59-$0.66-$0.07-$0.92N/AN/A2/28/2024Q4 2023SAVACassava Sciences-$0.40-$0.50-$0.10-$0.50N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ASNNASienna BiopharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A4.174.17CLRBCellectar BiosciencesN/A0.810.81ONCSOncoSec MedicalN/A0.890.89SAVACassava SciencesN/A9.139.13SNNASienna BiopharmaceuticalsN/A15.2715.27OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%CLRBCellectar Biosciences16.41%ONCSOncoSec Medical8.69%SAVACassava Sciences38.05%SNNASienna Biopharmaceuticals17.36%Insider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.57%CLRBCellectar Biosciences4.60%ONCSOncoSec Medical1.32%SAVACassava Sciences9.00%SNNASienna Biopharmaceuticals27.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics616.97 million16.03 millionNot OptionableCLRBCellectar Biosciences2032.26 million30.78 millionOptionableONCSOncoSec Medical404.55 million4.49 millionNot OptionableSAVACassava Sciences2943.25 million39.35 millionOptionableSNNASienna Biopharmaceuticals3930.91 millionN/ANot OptionableALRN, CLRB, ONCS, SAVA, and SNNA HeadlinesSourceHeadlineSienna Chirieleison scores 5 as Trinity girls lax downs outlasts Cumberland Valley, 10-9pennlive.com - April 26 at 12:11 AMSienna Chirieleison scores 14 goals as Trinity girls lax downs State College, 17-14pennlive.com - April 24 at 1:01 AMSienna Chirieleison scores 6 times as Trinity girls lax down Danville, 15-11pennlive.com - April 20 at 7:32 PMHigh school sports roundup: Sienna Warren scores OT winner for Long Beach; more lacrosse, baseball, softball and flag footballnewsday.com - April 16 at 11:01 PMSienna Jones, Devin Fitzpatrick earn SJS Lacky Awardsmantecabulletin.com - April 16 at 7:46 AMSienna Miller’s wedding and baby number three joymsn.com - April 16 at 7:46 AMSienna Wildgust, NHRA Pro Stock's Youngest Female Racer Is 'Breath of Fresh Air'msn.com - April 12 at 12:36 PMSienna Miller enjoys vacation with partner Oli Green in Costa Ricaladunliadinews.com - April 12 at 7:31 AM37th Street to close at end of month from Sienna Avenue to Stampede Drive in Evansgreeleytribune.com - April 11 at 9:16 PMTERRIFIER 3 Star Lauren LaVera Shares New Look At An Understandably Petrified Siennacomicbookmovie.com - April 10 at 2:59 PMPrincess Beatrice’s Best Friend Calls Her a ‘Fantastic’ Mom to ‘Gorgeous’ Daughter Siennausmagazine.com - April 10 at 2:59 PM2020 Toyota Siennajdpower.com - April 10 at 9:59 AMHollyoaks airs gunshot twist in Sienna Blake storymsn.com - April 9 at 7:05 PMSienna Mapelli Mozzi ‘looks exactly’ like mom Princess Beatricemsn.com - April 9 at 2:04 PMRevealed: Who Princess Beatrice's rarely seen daughter Sienna looks likemsn.com - April 9 at 8:55 AMPrincess Beatrice 'a fantastic mum' to daughter Sienna, stepmum to Wolfiemsn.com - April 8 at 6:49 PMHollyoaks star Anna Passey fears potential end of Sienna and Ste's friendshipmsn.com - April 6 at 10:44 AMSienna Chirieleison scores 300th career goal as Trinity girls lax defeats Palmyrapennlive.com - April 4 at 11:19 PMGolfer Sienna Mosquera finishes third in Floridaroyalgazette.com - April 3 at 3:59 PMStudent Athlete of the Week – Sienna Rodriguezkesq.com - April 3 at 1:18 AMHollyoaks confirms hostage drama for Sienna as Warren plan backfiresuk.news.yahoo.com - April 2 at 8:06 PMHollyoaks spoiler: Sienna records Warren's confessionmsn.com - April 2 at 8:06 PMHollyoaks spoiler: Ste and Sienna fear Warren's wrathdigitalspy.com - April 2 at 10:04 AMMorgan Coleman, Sienna Chirieleison, Alexis Kuntz lead Trinity lacrosse past Northernmsn.com - April 2 at 4:24 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAileron TherapeuticsNASDAQ:ALRNAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.Cellectar BiosciencesNASDAQ:CLRBCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.OncoSec MedicalNASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.Cassava SciencesNASDAQ:SAVACassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Sienna BiopharmaceuticalsNASDAQ:SNNASienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.